CsA

Jinan Military General Hospital · FDA-approved active Small molecule

CsA is a Calcineurin inhibitor Small molecule drug developed by Jinan Military General Hospital. It is currently FDA-approved for Organ transplant rejection prevention, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis), Graft-versus-host disease (GVHD). Also known as: Ciclosporin A, Cyclosporine, Neoral/Sandimmun.

CsA (cyclosporine A) is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

CsA (cyclosporine A) is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prevention, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis), Graft-versus-host disease (GVHD).

At a glance

Generic name	CsA
Also known as	Ciclosporin A, Cyclosporine, Neoral/Sandimmun
Sponsor	Jinan Military General Hospital
Drug class	Calcineurin inhibitor
Target	Calcineurin (protein phosphatase 2B)
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Mechanism of action

Cyclosporine A binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of IL-2 and other cytokines essential for T-cell proliferation and immune response, making it effective as an immunosuppressant in transplantation and autoimmune conditions.

Approved indications

• Organ transplant rejection prevention
• Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis)
• Graft-versus-host disease (GVHD)

Common side effects

• Nephrotoxicity
• Hypertension
• Tremor
• Gingival hyperplasia
• Hirsutism
• Infection
• Hyperkalemia

Key clinical trials

• Building Access to Food Through Systems and Solidarity (NA)
• Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
• Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
• Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)
• Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis (NA)
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
• Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CsA CI brief — competitive landscape report
• CsA updates RSS · CI watch RSS
• Jinan Military General Hospital portfolio CI

Frequently asked questions about CsA

What is CsA?

CsA is a Calcineurin inhibitor drug developed by Jinan Military General Hospital, indicated for Organ transplant rejection prevention, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis), Graft-versus-host disease (GVHD).

How does CsA work?

CsA (cyclosporine A) is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

What is CsA used for?

CsA is indicated for Organ transplant rejection prevention, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis), Graft-versus-host disease (GVHD).

Who makes CsA?

CsA is developed and marketed by Jinan Military General Hospital (see full Jinan Military General Hospital pipeline at /company/jinan-military-general-hospital).

Is CsA also known as anything else?

CsA is also known as Ciclosporin A, Cyclosporine, Neoral/Sandimmun.

What drug class is CsA in?

CsA belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is CsA in?

CsA is FDA-approved (marketed).

What are the side effects of CsA?

Common side effects of CsA include Nephrotoxicity, Hypertension, Tremor, Gingival hyperplasia, Hirsutism, Infection.

What does CsA target?

CsA targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related

• Drug class: All Calcineurin inhibitor drugs
• Target: All drugs targeting Calcineurin (protein phosphatase 2B)
• Manufacturer: Jinan Military General Hospital — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Organ transplant rejection prevention
• Indication: Drugs for Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis)
• Indication: Drugs for Graft-versus-host disease (GVHD)
• Also known as: Ciclosporin A, Cyclosporine, Neoral/Sandimmun